News & Updates

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023 by

A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

Machine perfusion techniques are effective and appear to be better than static cold storage (SCS) in patients who underwent liver transplantation, suggest the results of a meta-analysis.

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 by

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023

HCV pangenotypic DAA therapy in a patient with concomitant antipsychotic treatment

27 Oct 2023 by

A 43-year-old male former intravenous drug user presented with incidental findings of elevated alanine transaminase (ALT) levels in December 2021. The patient had depression and drug-induced psychosis associated with previous heroin, ketamine and methamphetamine use. He was on quetiapine 300 mg daily for his psychotic symptoms, pantoprazole 40 mg daily as needed for occasional acid reflux, and simvastatin 10 mg daily for hyperlipidaemia. He did not have hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfection.

HCV pangenotypic DAA therapy in a patient with concomitant antipsychotic treatment

27 Oct 2023

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023 by

Waitlisted registrants for liver transplantation (LT) who have nonalcoholic steatohepatitis (NASH) cirrhosis have a lower chance to receive a new organ and greater risk of waitlist mortality at 90 days and 1 year than patients with non-NASH cirrhosis, suggest the results of a Singapore study.

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023

Obeticholic acid shows therapeutic potential in LPAC syndrome

22 Oct 2023

The selective farnesoid-X receptor agonist obeticholic acid appears to improve symptoms of low phospholipid-associated cholelithiasis (LPAC) syndrome in patients who have inadequate response or intolerance to ursodeoxycholic acid, as shown in a small study.

Obeticholic acid shows therapeutic potential in LPAC syndrome

22 Oct 2023

Pegozafermin shows promise in NASH patients

13 Oct 2023

In the treatment of patients with nonalcoholic steatohepatitis (NASH), the glycoPEGylated FGF21 analogue pegozafermin appears to confer beneficial effects on hepatic and metabolic parameters while being well tolerated, according to the results of a phase 1b/2a clinical trial.

Pegozafermin shows promise in NASH patients

13 Oct 2023

News & Updates

Filter by Specialty:

Specialty:

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Bulevirtide-PegIFNα combo yields benefits for CHD patients

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission

Machine perfusion delivers positive outcomes for liver transplantation

Machine perfusion delivers positive outcomes for liver transplantation

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

HCV pangenotypic DAA therapy in a patient with concomitant antipsychotic treatment

HCV pangenotypic DAA therapy in a patient with concomitant antipsychotic treatment

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

Obeticholic acid shows therapeutic potential in LPAC syndrome

Obeticholic acid shows therapeutic potential in LPAC syndrome

Pegozafermin shows promise in NASH patients

Pegozafermin shows promise in NASH patients